P0745 Effectiveness of Switching to Subcutaneous Infliximab in Inflammatory Bowel Disease Patients with Inadequate Biochemical Response during Intravenous Administration

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, especially for patients with inadequate responses. This study investigates the effectiveness of switching from IV to SC-IFX in patients with inadequate biochemical response during IV maintenance therapy. Methods A retrospective study enrolled IBD patients who transitioned to SC-IFX after demonstrating inadequate biochemical response during IV maintenance therapy. The study collected data of demographics of patients and dose and therapies administered prior to the IV-IFX. Primary outcomes included improvements in C-reactive protein (CRP) or fecal calprotectin (FC) levels. This study evaluated the trough levels and its differences between pre- and post-switching. Results Among 44 patients included, 10 exhibited CRP elevation before the switch, with 6 showing normalization post-switch. Similarly, 42 patients had elevated FC levels pre-switch, with 26 experiencing reductions post-switch. Trough levels increased after the switch. However, there were no significant differences in trough levels between responders and non-responders. Conclusion This study aims to investigate the transition therapy of IV to SC-IFX in patients with inadequate biochemical response. This suggests that SC-IFX could be a viable alternative in the management of IBD. However, further research is necessary to evaluate its efficacy in a larger population of patients who exhibit inadequate responses during IV-IFX maintenance therapy. References et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362, 1383-1395. http://doi.org/10.1056/NEJMoa0904492 (2010). et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58, 501-508. http://doi.org/10.1136/gut.2008.163642 (2009). et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549. http://doi.org/10.1016/s0140-6736(02)08512-4 (2002).J Clin Gastroenterol 49, 582-588. http://doi.org/10.1097/mcg.0000000000000319 (2015). et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380, 1909-1915. http://doi.org/10.1016/s0140-6736(12)61084-8 (2012). et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 67, 237-243. http://doi.org/10.1136/gutjnl-2016-313060 (2018). et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130, 1054-1061. http://doi.org/10.1053/j.gastro.2006.02.014 (2006). et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340, 1398-1405. http://doi.org/10.1056/nejm199905063401804 (1999). et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353, 2462-2476. http://doi.org/10.1056/NEJMoa050516 (2005). et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350, 876-885. http://doi.org/10.1056/NEJMoa030815 (2004). et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58, 492-500. http://doi.org/10.1136/gut.2008.155812 (2009). et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337, 1029-1035. http://doi.org/10.1056/nejm199710093371502 (1997).Clin Drug Investig 42, 477-489. http://doi.org/10.1007/s40261-022-01162-6 (2022). et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 13, 1868078. http://doi.org/10.1080/19420862.2020.1868078 (2021). et al. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 39, 2342-2364. http://doi.org/10.1007/s12325-021-01990-6 (2022). et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 160, 2340-2353. http://doi.org/10.1053/j.gastro.2021.02.068 (2021). et al. Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter? Crohns Colitis 360 5, otad040. http://doi.org/10.1093/crocol/otad040 (2023).Medicine (Baltimore) 101, e30683. http://doi.org/10.1097/md.0000000000030683 (2022). et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160, 1570-1583. http://doi.org/10.1053/j.gastro.2020.12.031 (2021).Gastroenterology 154, S-1371 (2018). et al. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. J Crohns Colitis 16, 1059-1069. http://doi.org/10.1093/ecco-jcc/jjac009 (2022). et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 21, 2338-2346.e2333. http://doi.org/10.1016/j.cgh.2022.08.011 (2023). et al. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res 22, 1319. http://doi.org/10.1186/s12913-022-08683-y (2022). et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 10. http://doi.org/10.3390/biomedicines10092130 (2022). et al. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study. Inflamm Bowel Dis 30, 517-528. http://doi.org/10.1093/ibd/izad094 (2024). et al. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 69, 1432-1440. http://doi.org/10.1136/gutjnl-2019-319699 (2020). et al. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis 13, 1410-1417. http://doi.org/10.1093/ecco-jcc/jjz081 (2019).Korean J Intern Med 37, 885-894. http://doi.org/10.3904/kjim.2022.138 (2022).